1 / 1
High-Quality Mazdutide CAS 2259884-03-0: Leading China Suppliers & Factory for Dual GCG/GLP-1 Agonist for Weight Loss Manufacturer, Quotes
Product Description
Mazdutide is the world's first dual GCG/GLP-1 receptor agonist approved for weight loss, offering a unique mechanism that enhances weight-loss efficacy while reducing visceral fat and delivering comprehensive metabolic benefits, named by Fierce Pharma as one of the top ten most anticipated drugs globally in 2025.
Therapeutic Areas
With China approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugs
With a first-in-class approval in China, Eli Lilly’s GLP-1 development engine has delivered yet again on the obesity front—although local biopharma outfit Innovent Biologics will be the one to reap the rewards in the near term.
In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s dual GLP-1/glucagon (GCP) receptor agonist mazdutide for chronic weight management in Chinese adults who are overweight or have obesity.
Crucially, patients must also have at least one weight-related comorbidity, such as high blood sugar or blood pressure, according to a statement (Chinese) from the country’s drug regulator.
Outlook & Development
The green light earns mazdutide the distinction of being the world’s first dual GCG/GLP-1 med, Innovent said in a June 27 press release. Innovent paid an undisclosed sum to secure the Chinese rights to mazdutide from Lilly in 2019, while Lilly continues to hold the rights to the metabolic drug outside of China, where it has yet to win approval.
Mazdutide, as a new entrant in the booming GLP-1 scene for obesity, recently ranked among Fierce Pharma’s top 10 most anticipated drug launches of 2025. That report leveraged data on prospective launches from intelligence and analytics firm Evaluate, which has estimated that the drug could reach $1.3 billion in 2030 sales.
By targeting the GCG receptor, Lilly and Innovent figure mazdutide should help increase the body’s energy expenditure, spurring changes in the liver, brain and white and brown adipose tissue that complement the reduced energy intake triggered by GLP-1 activation.
China’s drug regulator based its approval on data from Innovent’s phase 3 GLORY-1 study in more than 600 adults in China who are overweight or obese. At the study’s 48-week mark, patients on mazdutide 4 mg, mazdutide 6 mg and placebo achieved an average weight loss relative to baseline of 12%, 14.8% and 0.5%, respectively.
Frequently Asked Questions
What makes Mazdutide unique among weight loss drugs?
Mazdutide is the world's first dual GCG/GLP-1 receptor agonist approved for weight loss. It enhances weight-loss efficacy while reducing visceral fat and providing comprehensive metabolic benefits by targeting both receptors to increase energy expenditure and reduce energy intake.
Who holds the rights to Mazdutide?
Innovent Biologics secured the Chinese rights to Mazdutide from Eli Lilly in 2019. Eli Lilly continues to hold the rights to the drug outside of China.
What are the specific requirements for patients to be prescribed Mazdutide in China?
According to China's NMPA, Mazdutide is approved for Chinese adults who are overweight or have obesity, provided they also have at least one weight-related comorbidity, such as high blood sugar or high blood pressure.
How does targeting the GCG receptor aid in weight loss?
Targeting the GCG receptor helps increase the body's energy expenditure. This spurs beneficial changes in the liver, brain, and both white and brown adipose tissue, which complements the reduced energy intake caused by GLP-1 activation.
What were the results of the phase 3 GLORY-1 study?
In the 48-week phase 3 GLORY-1 study involving over 600 adults in China, patients taking Mazdutide 4 mg achieved a 12% average weight loss, and those on 6 mg achieved 14.8%, compared to just 0.5% for the placebo group.
What is the market expectation for Mazdutide?
Mazdutide is named by Fierce Pharma as one of the top ten most anticipated drug launches globally in 2025. Market analytics firm Evaluate estimates that the drug could reach $1.3 billion in sales by 2030.
